HC Wainwright Issues Positive Forecast for ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price

Key Points

• HC Wainwright raised the price target for ANI Pharmaceuticals from $93.00 to $121.00, indicating a potential upside of 24.81% from the current stock price.
• The company recently announced earnings of $1.80 EPS, exceeding analysts' expectations by $0.38 and reporting a significant 53.2% increase in quarterly revenue year-over-year.
• Insiders sold 412,830 shares of ANI Pharmaceuticals stock worth over $36 million in the last 90 days, with 12.70% of shares currently held by corporate insiders.

ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) had its price objective hoisted by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday morning, MarketBeat.com reports. They currently have a buy rating on the specialty pharmaceutical company's stock. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q3 2025 earnings at $1.21 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $5.73 EPS and FY2026 earnings at $6.53 EPS.

A number of other equities analysts have also recently weighed in on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a "buy" rating in a research note on Monday, September 8th. Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Piper Sandler restated an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $93.00.

ANI Pharmaceuticals Trading Down 0.7%

ANI Pharmaceuticals stock traded down $0.69 during midday trading on Wednesday, hitting $96.79. 346,251 shares of the stock were exchanged, compared to its average volume of 380,949. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The stock's 50-day simple moving average is $82.71 and its 200 day simple moving average is $70.98. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -125.70 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. During the same quarter in the prior year, the company posted $1.02 EPS. The business's revenue for the quarter was up 53.2% on a year-over-year basis. On average, equities analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, Director Antonio R. Pera sold 7,292 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $94.94, for a total value of $692,302.48. Following the transaction, the director owned 22,660 shares in the company, valued at approximately $2,151,340.40. This represents a 24.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew J. Leonard sold 2,528 shares of the company's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the transaction, the director directly owned 6,864 shares of the company's stock, valued at $622,015.68. This trade represents a 26.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 412,830 shares of company stock worth $36,397,254 over the last three months. Company insiders own 11.10% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Rubric Capital Management LP grew its holdings in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after buying an additional 200,998 shares during the last quarter. Aberdeen Group plc grew its stake in shares of ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock valued at $28,059,000 after purchasing an additional 181,134 shares during the last quarter. Woodline Partners LP acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $11,144,000. Teacher Retirement System of Texas raised its stake in shares of ANI Pharmaceuticals by 3,156.3% during the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company's stock worth $9,617,000 after purchasing an additional 142,854 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 17.2% during the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company's stock worth $56,251,000 after purchasing an additional 126,500 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.